Understanding RSV Vaccine Recommendations for Seniors

What RSV Is and Why Seniors Face Higher Risk

Respiratory syncytial virus, or RSV, is a common virus that affects the lungs and airways. Most children and adults get RSV at some point in their lives. The virus spreads through respiratory droplets when an infected person coughs or sneezes. You can catch RSV by breathing in these droplets or by touching your face after touching a contaminated surface.

Learn About AARP Life Insurance Account Login →

RSV typically causes mild cold-like symptoms in healthy adults and older children. Symptoms include a runny nose, cough, sore throat, and low-grade fever. Most people recover within one to two weeks. However, RSV can become serious in certain groups of people, particularly adults aged 60 and older.

Seniors face higher risks from RSV for several reasons. As people age, their immune systems naturally weaken. This means older adults have a harder time fighting off infections. Additionally, many seniors have chronic health conditions like heart disease, lung disease, or diabetes. These conditions make complications from RSV more likely. People with weakened immune systems due to medical treatments or certain medications are also at increased risk.

In the United States, RSV causes an estimated 14,000 deaths per year among adults aged 60 and older, according to CDC data. About 177,000 older adults are hospitalized annually due to RSV. These hospitalizations often involve serious complications like pneumonia, bronchiolitis, or acute respiratory distress. Some seniors experience such severe illness that they require oxygen support or mechanical ventilation.

The risk increases further for seniors living in certain situations. Those in nursing homes or assisted living facilities face higher exposure rates. Seniors with heart disease have particularly poor outcomes from RSV infection. People with chronic obstructive pulmonary disease (COPD) also experience more severe symptoms.

Takeaway: RSV is a serious concern for seniors because age and existing health conditions combine to make the virus more dangerous. Understanding your personal risk factors can help you make informed decisions about vaccination.

Overview of RSV Vaccines Available for Adults

Until recently, no vaccines for RSV were available for adults of any age. This changed in 2023 when the U.S. Food and Drug Administration approved two RSV vaccines specifically designed for older adults. Both vaccines are now available and can help prevent RSV disease in seniors.

Remove Yahoo Search From Chrome Easily →

The first vaccine approved was Arexvy, manufactured by GlaxoSmithKline. The second was Abrysvo, made by Pfizer. Both vaccines are intended for adults aged 60 and older. These are inactivated vaccines, meaning they contain killed or weakened versions of the virus, not live virus. They work by teaching your immune system to recognize RSV and fight it off if you encounter it later.

Arexvy uses a technology called recombinant subunit vaccination. This means the vaccine contains a specific piece of the RSV virus that has been created in a laboratory. Your immune system learns to recognize this piece and develops protection. Abrysvo uses a different approach involving modified RSV proteins. Both approaches have been shown to reduce the risk of developing severe RSV disease in older adults.

Clinical trials tested both vaccines before approval. Arexvy was studied in a trial involving over 30,000 adults aged 60 and older. The vaccine was found to reduce the risk of RSV lower respiratory tract disease by about 82 percent in participants aged 60 to 74. In adults aged 75 and older, the vaccine reduced risk by approximately 69 percent. Abrysvo showed similar effectiveness, with a reduction in RSV lower respiratory tract disease risk of around 82 to 94 percent depending on age group.

Both vaccines are administered as a single dose. You receive one injection, typically in the upper arm muscle. This is different from some other vaccines that require multiple doses or boosters. Once you receive the vaccine, your immune system begins developing protection that builds over weeks.

Takeaway: Two RSV vaccines are currently available for seniors. Both are single-dose vaccines administered by injection, and clinical trials showed significant reductions in severe RSV disease risk. The choice between the two often depends on availability and individual circumstances.

Current CDC and Medical Organization Recommendations

The Centers for Disease Control and Prevention (CDC) provides guidance on RSV vaccination for older adults. In June 2023, shortly after vaccine approval, the CDC's Advisory Committee on Immunization Practices (ACIP) made recommendations about who should receive RSV vaccines.

Get Your Free Michelin Tire Warranty Information Guide →

The CDC recommends that adults aged 60 and older discuss RSV vaccination with their healthcare provider. This is called a shared clinical decision-making approach. Rather than a blanket recommendation for all seniors, the CDC acknowledges that the decision should be individualized based on factors specific to each person.

The CDC particularly encourages vaccination for older adults with certain risk factors. These include chronic heart disease, chronic lung disease (including asthma and COPD), diabetes, or a weakened immune system. Adults living in long-term care facilities or other congregate settings are also considered higher priority. People aged 75 and older are recommended to discuss vaccination regardless of their health status, as age itself is a significant risk factor.

Other major medical organizations have weighed in on RSV vaccination. The American Academy of Family Physicians recommends shared decision-making for adults aged 60 and older, with particular emphasis on those with chronic conditions. The American College of Physicians similarly recommends individualized assessment. The Infectious Diseases Society of America suggests offering vaccination to adults aged 60 and older, particularly those with chronic medical conditions or immunocompromise.

It is important to note that recommendations may evolve as more data becomes available. Healthcare providers continue to monitor vaccine safety and effectiveness. Recommendations might change based on new research or data about real-world vaccine performance. This is why speaking with your doctor about your specific situation remains important, even if general recommendations exist.

Many states and healthcare systems have incorporated RSV vaccination into their senior healthcare offerings. Medicare began covering RSV vaccines for beneficiaries aged 60 and older in July 2023. This coverage decision reflects confidence in the vaccines' safety and effectiveness for this age group.

Takeaway: Major health organizations recommend that seniors aged 60 and older discuss RSV vaccination with their doctor, with particular focus on those with chronic health conditions or age 75 and older. Coverage through Medicare indicates the vaccines are considered a standard preventive option.

Understanding Risk Factors and Personal Circumstances

Deciding whether to receive an RSV vaccine depends partly on your individual risk factors. Some seniors face substantially higher risks from severe RSV disease than others. Understanding which risk factors apply to you can inform conversations with your healthcare provider.

Learn About Redeeming United Airlines Rewards Points →

Age is itself a risk factor. Adults aged 75 and older experience more severe outcomes from RSV than those aged 60 to 74. The CDC specifically notes that vaccination may be particularly beneficial for the oldest seniors. However, even seniors in their 60s can develop serious RSV illness, so age alone should not determine your decision.

Chronic health conditions significantly increase your risk. People with chronic heart disease face particularly serious outcomes. This includes those with conditions like heart failure, coronary artery disease, or arrhythmias. Chronic lung disease is another major risk factor. This includes COPD, asthma, pulmonary fibrosis, or other conditions affecting lung function. People with diabetes also face increased risks. Those with poorly controlled blood sugar may have even higher risk.

Immune system status matters significantly. People taking immunosuppressive medications—such as those with autoimmune diseases or those who have received organ transplants—face higher risks. Cancer patients undergoing active treatment may have weakened immunity. People living with HIV may be at increased risk, particularly if their CD4 count is low. Even older adults without diagnosed conditions may have age-related immune weakening that makes RSV more dangerous.

Your living situation affects exposure risk. Adults in nursing homes or assisted living facilities are frequently exposed to RSV. Outbreaks can occur in these settings, putting all residents at risk. Similarly, seniors who live with young children or work in childcare settings face more exposure, since children frequently carry RSV. However, exposure risk is separate from severity risk—where you live affects how likely you are to catch RSV, while your health status affects how sick you might become.

Consider your recent RSV history as well. If you had RSV infection in the previous year, you may have some residual immunity. However, this